IER2 and acute myeloid leukemia: ELK3, IER2, GLUD2 and MYSM1 showed consistently higher relative abundances in the evaluated samples from primary AML patients and relapse patients than that in the samples from patients with CR or the healthy controls (Fig. 6H).